Jan-28-21 Upgrade
BTIG Research
Neutral → Buy
$140
Sep-11-20 Initiated
Wolfe Research
Outperform
$124
Jun-01-20 Downgrade
Goldman
Neutral → Sell
$84
Mar-05-20 Initiated
Citigroup
Buy
$96
Feb-13-20 Initiated
Goldman
Neutral
$96
Feb-06-20 Resumed
BTIG Research
Neutral
Jan-02-20 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Reiterated
BofA/Merrill
Buy
$81 → $90
Feb-07-19 Reiterated
BofA/Merrill
Buy
$73 → $81
Jan-02-19 Downgrade
Citigroup
Neutral → Sell
Nov-30-18 Upgrade
Goldman
Neutral → Buy
Oct-16-18 Initiated
Barclays
Overweight
$80
Jun-27-18 Initiated
Bernstein
Outperform
$73
Jan-30-18 Reiterated
Citigroup
Neutral
$59 → $64
Jan-25-18 Upgrade
William Blair
Mkt Perform → Outperform
Jan-25-18 Reiterated
Stifel
Buy
$63 → $71
Jan-03-18 Initiated
Evercore ISI
Outperform
Jan-02-18 Upgrade
Morgan Stanley
Equal-Weight → Overweight
Jan-02-18 Upgrade
JP Morgan
Neutral → Overweight
Oct-19-17 Reiterated
Stifel
Buy
$58 → $63
Mar-01-21 06:25AM
Feb-28-21 06:22AM
Feb-26-21 11:30AM
10:16AM
09:26AM
09:22AM
09:01AM
08:53AM
Feb-25-21 05:45PM
Feb-24-21 09:31AM
Feb-23-21 04:20PM Investor's Business Daily
09:40AM Investor's Business Daily
Feb-19-21 02:47PM
01:25PM
Feb-18-21 07:15AM Investor's Business Daily
Feb-17-21 12:35PM
Feb-16-21 04:09PM
Feb-12-21 11:47AM
10:38AM
10:05AM
09:19AM
09:17AM
08:58AM
08:30AM
06:40AM
Feb-11-21 08:49PM
12:24PM
11:47AM
10:35AM
09:11AM
08:50AM
07:47AM
06:55AM
Feb-10-21 12:00PM
11:31AM
10:18AM
10:14AM
Feb-09-21 09:59AM
09:56AM
09:41AM
06:50AM
Feb-08-21 01:21PM
09:14AM
Feb-07-21 05:58AM
Feb-06-21 10:59AM
Feb-05-21 11:09AM
09:50AM
06:01AM
02:00AM
Feb-04-21 01:34PM
12:25PM
11:30AM
11:25AM
09:30AM
09:29AM
09:22AM
08:07AM
08:06AM
07:47AM
07:30AM
Feb-03-21 10:42AM
10:30AM
09:48AM
08:16AM
Feb-02-21 01:11PM
12:20PM
10:10AM
09:39AM
08:35AM
05:50AM
03:53AM
Feb-01-21 01:05PM
12:00PM
11:34AM
08:00AM
Jan-31-21 11:01PM
Jan-30-21 06:35AM
Jan-29-21 06:52AM
Jan-28-21 11:07PM
11:15AM
08:03AM
06:20AM
Jan-27-21 04:24PM Investor's Business Daily
04:15PM Investor's Business Daily
03:00PM
03:00PM
10:49AM
10:42AM
09:54AM
08:45AM
08:15AM
08:10AM
07:30AM
07:21AM
04:01AM
Jan-26-21 10:10AM
07:45AM
07:16AM
Jan-22-21 08:29PM
Jan-20-21 08:22AM
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Meniere's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kumbier Michelle Director Feb 23 Buy 122.50 2,040 249,900 7,296 Feb 25 06:05 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Feb 22 Sale 121.84 400 48,734 75,706 Feb 23 07:05 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Feb 16 Sale 128.49 505 64,887 63,373 Feb 18 05:57 PM Funck Robert E EXECUTIVE VICE PRESIDENT Feb 02 Option Exercise 39.12 31,325 1,225,434 193,542 Feb 04 06:56 PM MANNING JOSEPH J SENIOR VICE PRESIDENT Feb 02 Sale 123.03 3,130 385,084 59,681 Feb 03 07:20 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Feb 01 Option Exercise 38.78 203,393 7,887,902 355,289 Feb 03 07:10 PM Scoggins Christopher J SENIOR VICE PRESIDENT Feb 01 Option Exercise 44.83 45,000 2,017,200 84,706 Feb 03 07:14 PM MANNING JOSEPH J SENIOR VICE PRESIDENT Feb 01 Option Exercise 38.40 18,750 720,000 81,561 Feb 03 07:20 PM MANNING JOSEPH J SENIOR VICE PRESIDENT Feb 01 Sale 122.79 18,750 2,302,264 62,811 Feb 03 07:20 PM Scoggins Christopher J SENIOR VICE PRESIDENT Feb 01 Sale 123.24 45,000 5,545,800 39,706 Feb 03 07:14 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Feb 01 Sale 123.47 203,393 25,113,252 151,896 Feb 03 07:10 PM NOVAKOVIC PHEBE N Director Dec 04 Option Exercise 34.97 14,681 513,431 45,794 Dec 08 05:58 PM NOVAKOVIC PHEBE N Director Dec 04 Sale 107.28 4,790 513,849 41,004 Dec 08 05:58 PM OSBORN WILLIAM A Director Nov 24 Option Exercise 43.64 21,448 935,991 79,745 Nov 25 05:41 PM Funck Robert E Executive Vice President & CFO Oct 26 Option Exercise 38.40 83,333 3,199,987 265,550 Oct 28 06:33 PM Funck Robert E Executive Vice President & CFO Oct 26 Sale 108.83 83,333 9,068,955 182,217 Oct 28 06:33 PM Wainer Andrea F Executive Vice President Sep 30 Option Exercise 38.40 30,000 1,152,000 74,080 Oct 01 05:50 PM Wainer Andrea F Executive Vice President Sep 30 Sale 107.01 30,000 3,210,360 44,080 Oct 01 05:50 PM Wainer Andrea F Executive Vice President Sep 23 Sale 102.47 3,650 374,031 44,080 Sep 25 05:06 PM WOODGRIFT RANDEL WILLIAM Senior Vice President Sep 11 Sale 105.28 2,500 263,200 46,267 Sep 15 06:14 PM Ginascol John F Executive Vice President Sep 01 Option Exercise 43.16 72,098 3,111,584 136,775 Sep 03 06:33 PM BIRD ROGER Senior Vice President Sep 01 Sale 108.73 6,290 683,929 56,630 Sep 03 05:52 PM CAPEK JOHN M Executive Vice President Aug 27 Option Exercise 27.03 52,300 1,413,857 369,100 Aug 31 06:27 PM Salvadori Daniel Gesua Sive Executive Vice President Aug 27 Option Exercise 47.00 42,479 1,996,513 144,912 Aug 31 06:28 PM Salvadori Daniel Gesua Sive Executive Vice President Aug 27 Sale 111.86 42,479 4,751,701 102,433 Aug 31 06:28 PM CAPEK JOHN M Executive Vice President Aug 27 Sale 111.86 52,300 5,850,278 316,800 Aug 31 06:27 PM NOVAKOVIC PHEBE N Director Jul 23 Option Exercise 25.05 3,739 93,677 32,046 Jul 27 05:06 PM NOVAKOVIC PHEBE N Director Jul 23 Sale 100.78 933 94,026 31,113 Jul 27 05:06 PM AUSTIN ROXANNE S Director Jul 22 Sale 99.80 6,844 683,038 40,043 Jul 23 05:07 PM PEDERSON MICHAEL J Senior Vice President Jul 21 Option Exercise 0.00 23,008 0 96,899 Jul 23 05:04 PM PEDERSON MICHAEL J Senior Vice President Jul 21 Sale 98.00 23,008 2,254,784 73,891 Jul 23 05:04 PM Earnhardt Lisa D Executive Vice President Jun 10 Sale 90.84 872 79,216 72,074 Jun 12 05:07 PM LANE ANDREW H Executive Vice President May 05 Option Exercise 43.82 80,000 3,505,314 145,822 May 07 05:02 PM LANE ANDREW H Executive Vice President May 05 Sale 92.00 80,000 7,360,104 65,822 May 07 05:02 PM WOODGRIFT RANDEL WILLIAM Senior Vice President Apr 28 Sale 93.18 3,724 347,012 48,767 Apr 30 06:34 PM Funck Robert E Executive Vice President & CFO Apr 21 Option Exercise 36.42 36,700 1,336,638 206,072 Apr 23 09:27 PM Contreras Jaime Senior Vice President Apr 21 Option Exercise 57.12 108,412 6,192,995 145,431 Apr 23 09:26 PM CAPEK JOHN M Executive Vice President Apr 21 Option Exercise 22.39 50,100 1,121,834 366,900 Apr 23 09:34 PM Ginascol John F Executive Vice President Apr 21 Option Exercise 38.40 63,200 2,426,880 129,645 Apr 23 09:41 PM CAPEK JOHN M Executive Vice President Apr 21 Sale 95.87 50,100 4,803,326 316,800 Apr 23 09:34 PM Scoggins Christopher J Senior Vice President Apr 21 Sale 96.10 414 39,785 39,706 Apr 23 09:28 PM Ginascol John F Executive Vice President Apr 21 Sale 96.00 63,200 6,067,051 66,445 Apr 23 09:41 PM Boudreau Philip P Vice President Mar 13 Sale 82.00 10,600 869,200 22,463 Mar 16 06:47 PM Watkin Jared Senior Vice President Mar 06 Sale 82.00 8,248 676,336 68,696 Mar 10 05:06 PM Funck Robert E Executive Vice President & CFO Mar 02 Sale 77.89 1,356 105,619 169,372 Mar 03 05:28 PM WOODGRIFT RANDEL WILLIAM Senior Vice President Mar 02 Sale 77.89 1,420 110,604 53,859 Mar 03 05:27 PM BIRD ROGER Senior Vice President Mar 02 Sale 77.89 666 51,875 62,920 Mar 03 05:23 PM DALE MICHAEL D Senior Vice President Mar 02 Sale 77.89 787 61,299 34,763 Mar 03 05:21 PM Ginascol John F Executive Vice President Mar 02 Sale 77.63 6,606 512,805 66,445 Mar 03 05:20 PM Contreras Jaime Senior Vice President Mar 02 Sale 77.89 2,001 155,858 37,019 Mar 03 05:19 PM Watkin Jared Senior Vice President Mar 02 Sale 77.89 1,761 137,164 76,944 Mar 03 05:19 PM ALLEN HUBERT L Executive Vice President Mar 02 Sale 77.89 1,208 94,091 151,896 Mar 03 05:16 PM Scoggins Christopher J Senior Vice President Mar 02 Sale 77.89 1,240 96,584 41,168 Mar 03 05:15 PM Salvadori Daniel Gesua Sive Executive Vice President Mar 02 Sale 77.89 999 77,812 103,493 Mar 03 05:16 PM BRYNELSEN CHARLES Senior Vice President Mar 02 Sale 77.89 1,781 138,722 45,460 Mar 03 05:13 PM Wainer Andrea F Executive Vice President Mar 02 Sale 77.89 1,429 111,305 49,498 Mar 03 05:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite